<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06429</drugbank-id>
  <name>Talnetant</name>
  <description>Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.</description>
  <cas-number>174636-32-9</cas-number>
  <unii>CZ3T9T146K</unii>
  <average-mass>382.4544</average-mass>
  <monoisotopic-mass>382.168127958</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A6850</ref-id>
        <pubmed-id>17728699</pubmed-id>
        <citation>Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J: In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. Epub 2007 Aug 29.</citation>
      </article>
      <article>
        <ref-id>A6851</ref-id>
        <pubmed-id>17727393</pubmed-id>
        <citation>Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ: Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil. 2007 Sep;19(9):732-43.</citation>
      </article>
      <article>
        <ref-id>A6852</ref-id>
        <pubmed-id>16044668</pubmed-id>
        <citation>Evangelista S: Talnetant GlaxoSmithKline. Curr Opin Investig Drugs. 2005 Jul;6(7):717-21.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in schizophrenia and schizoaffective disorders, irritable bowel syndrome (IBS), and chronic obstructive pulmonary disease (COPD).</indication>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.</description>
    <direct-parent>Phenylquinolines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Quinolines and derivatives</class>
    <subclass>Phenylquinolines</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroxypyridines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylpropanes</alternative-parent>
    <alternative-parent>Phenylpyridines</alternative-parent>
    <alternative-parent>Pyridinecarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Quinoline carboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous acids</alternative-parent>
    <substituent>2-phenylpyridine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxypyridine</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylpropane</substituent>
    <substituent>Phenylquinoline</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridine carboxylic acid or derivatives</substituent>
    <substituent>Quinoline-4-carboxamide</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Vinylogous acid</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002012</drugbank-id>
      <name>Talnetant hydrochloride</name>
      <unii>C1ZIJ8F59E</unii>
      <cas-number>204519-66-4</cas-number>
      <inchikey>BHCSUEHQURQVLD-BDQAORGHSA-N</inchikey>
      <average-mass>418.92</average-mass>
      <monoisotopic-mass>418.1448057</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Receptors, Neurokinin-3, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.98</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.27e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>6.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>talnetant</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>382.4544</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>382.168127958</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCC(NC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C25H22N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BIAVGWDGIJKWRM-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>62.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>114.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>42.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>2.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>133090</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>117450</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50074819</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Talnetant</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL275544</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0002371</id>
      <name>Neuromedin-K receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14034</ref-id>
            <pubmed-id>17172464</pubmed-id>
            <citation>Tian G, Wilkins D, Scott CW: Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15.</citation>
          </article>
          <article>
            <ref-id>A6850</ref-id>
            <pubmed-id>17728699</pubmed-id>
            <citation>Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J: In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. Epub 2007 Aug 29.</citation>
          </article>
          <article>
            <ref-id>A38969</ref-id>
            <pubmed-id>9190866</pubmed-id>
            <citation>Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW: Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther. 1997 Jun;281(3):1303-11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P29371" source="Swiss-Prot">
        <name>Neuromedin-K receptor</name>
        <general-function>Tachykinin receptor activity</general-function>
        <specific-function>This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K &gt; substance K &gt; substance P.</specific-function>
        <gene-name>TACR3</gene-name>
        <locus>4q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>85-107
118-139
160-181
202-222
246-270
300-321
335-359</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.61</theoretical-pi>
        <molecular-weight>52201.35</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TACR3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M89473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NK3R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neurokinin B receptor</synonym>
          <synonym>NK-3 receptor</synonym>
          <synonym>NK-3R</synonym>
          <synonym>NK3R</synonym>
          <synonym>NKR</synonym>
          <synonym>TAC3R</synonym>
          <synonym>Tachykinin receptor 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016769|Neuromedin-K receptor
MATLPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQLLDQAGNLSSSPSALGL
PVASPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWIILAHKRMRTVT
NYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIYSMTAIA
VDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPEG
PKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKM
MIIVVMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLN
KRFRAGFKRAFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADT
TRSSRKKRATPRDPSFNGCSRRNSKSASATSSFISSPYTSVDEYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016770|Neuromedin-K receptor (TACR3)
ATGGCCACTCTCCCAGCAGCAGAAACCTGGATAGACGGGGGTGGAGGCGTGGGTGCAGAC
GCCGTGAACCTGACCGCCTCGCTAGCTGCCGGGGCGGCCACGGGGGCAGTTGAGACTGGG
TGGCTGCAACTGCTGGACCAAGCTGGCAACCTCTCCTCCTCCCCTTCCGCGCTGGGACTG
CCTGTGGCTTCCCCCGCGCCCTCCCAGCCCTGGGCCAACCTCACCAACCAGTTCGTGCAG
CCGTCCTGGCGCATCGCGCTCTGGTCCCTGGCGTATGGTGTGGTGGTGGCAGTGGCAGTT
TTGGGAAATCTCATCGTCATCTGGATCATCCTGGCCCACAAGCGCATGAGGACTGTCACC
AACTACTTCCTTGTGAACCTGGCTTTCTCCGACGCCTCCATGGCCGCCTTCAACACGTTG
GTCAATTTCATCTACGCGCTTCATAGCGAGTGGTACTTTGGCGCCAACTACTGCCGCTTC
CAGAACTTCTTTCCTATCACAGCTGTGTTCGCCAGCATCTACTCCATGACGGCCATTGCG
GTGGACAGGTATATGGCTATTATTGATCCCTTGAAACCCAGACTGTCTGCTACAGCAACC
AAGATTGTCATTGGAAGTATTTGGATTCTAGCATTTCTACTTGCCTTCCCTCAGTGTCTT
TATTCCAAAACCAAAGTCATGCCAGGCCGTACTCTCTGCTTTGTGCAATGGCCAGAAGGT
CCCAAACAACATTTCACTTACCATATTATCGTCATTATACTGGTGTACTGTTTCCCATTG
CTCATCATGGGTATTACATACACCATTGTTGGAATTACTCTCTGGGGAGGAGAAATCCCA
GGAGATACCTGTGACAAGTATCATGAGCAGCTAAAGGCCAAAAGAAAGGTTGTCAAAATG
ATGATTATTGTTGTCATGACATTTGCTATCTGCTGGCTGCCCTATCATATTTACTTCATT
CTCACTGCAATCTATCAACAACTAAATAGATGGAAATACATCCAGCAGGTCTACCTGGCT
AGCTTTTGGCTGGCAATGAGCTCAACCATGTACAATCCCATCATCTACTGCTGTCTGAAT
AAAAGATTTCGAGCTGGCTTCAAGAGAGCATTTCGCTGGTGTCCTTTCATCAAAGTTTCC
AGCTATGATGAGCTAGAGCTCAAGACCACCAGGTTTCATCCAAACCGGCAAAGCAGTATG
TACACCGTGACCAGAATGGAGTCCATGACAGTCGTGTTTGACCCCAACGATGCAGACACC
ACCAGGTCCAGTCGGAAGAAAAGAGCAACGCCAAGAGACCCAAGTTTCAATGGCTGCTCT
CGCAGGAATTCCAAATCTGCCTCCGCCACTTCAAGTTTCATAAGCTCACCCTATACCTCT
GTGGATGAATATTCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>tachykinin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyperosmotic salinity response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tachykinin receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>